Edition:
United Kingdom

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

0.43USD
21 Sep 2018
Change (% chg)

$0.01 (+2.02%)
Prev Close
$0.42
Open
$0.41
Day's High
$0.45
Day's Low
$0.40
Volume
134,245
Avg. Vol
66,563
52-wk High
$8.95
52-wk Low
$0.40

Latest Key Developments (Source: Significant Developments)

Flex Pharma Reports Q2 LOSS PER SHARE $0.50
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Flex Pharma Inc ::FLEX PHARMA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $245,500.HAS STOPPED CLINICAL TRIALS IN MND AND CMT, WIND-DOWN OF THOSE STUDIES IS EXPECTED TO BE COMPLETED IN THE Q3 2018.  Full Article

Flex Pharma Q3 loss per share $0.54
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc ::Flex Pharma reports third quarter 2017 financial results.Q3 loss per share $0.54.Q3 revenue $414,000 versus I/B/E/S view $477,000.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - ‍expects to have sufficient capital to fund operations into early 2019​.  Full Article

Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc :Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS.Flex Pharma - ‍data from exploratory phase 2 trial of FLX-787 showed statistically significant reduction in cramp-associated pain intensity & stiffness​.Flex Pharma Inc - ‍FLX-787 was generally well tolerated​.  Full Article

Flex Pharma initiates CMT phase 2 trial with FLX-787 in US
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Flex Pharma Inc :Flex Pharma initiates CMT phase 2 trial with FLX-787 in US.Flex Pharma Inc - ‍ALS phase 2 trial currently underway​.Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​.  Full Article

Flex Pharma to scrap two mid-stage neuromuscular disease trials

U.S. drug developer Flex Pharma Inc said on Wednesday it plans to stop two ongoing mid-stage trials, testing its lead drug to treat neuromuscular diseases, following safety concerns.